Every Form 4 that eXoZymes Inc. (EXOZ) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow EXOZ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EXOZ filings page.
EXOZYMES INC. Chief Commercial Officer Damien Alan Perriman converted 3,922 restricted stock units into 3,922 common shares on October 9, 2026, on a one-for-one basis with no consideration paid. The units came from a grant of 62,759 on April 1, 2026, vesting periodically; 39,225 restricted stock units were reported following the conversion. On October 12, 2026, he sold 3,729 common shares to cover tax withholding obligations, at a weighted-average price of $5.2096 per share across trades priced from $5.15 to $5.25. No Rule 10b5-1 plan is reported.
Exozymes Inc. amended a prior report to correct an erroneously reported conversion by Tyler Paz Korman, its Chief Scientific Officer. The 32,964 restricted stock units did not convert on August 19, 2026, and no shares were issued. After removing the erroneous entry, reported holdings were 79,104 outstanding restricted stock units and 729,123 shares of common stock.
Exozymes Inc. director Edgardo Javier Rayo received a grant of 25,000 stock options on October 1, 2026, with an exercise price of $6.28 per share and an expiration date of October 1, 2033. The options vest in twelve quarterly installments: eleven installments of 2,083 shares and a final installment of 2,087 shares, beginning December 31, 2026 and ending September 30, 2029, subject to his continued service. The report also lists his direct ownership of 77,909 common shares on October 1, 2026.
Christopher A. Marlett, a director and 10% owner of EXOZ, received a direct award of options to buy 10,000 shares on October 1, 2026, with a $6.28 exercise price and an October 1, 2033 expiration. The options vest quarterly from December 31, 2026, through September 30, 2029, subject to his continued service with the issuer. Separately, MDB Capital Holdings, LLC held 3,808,476 common shares as of October 1, 2026. Marlett has voting and dispositive authority over those shares and disclaims any interest except to the extent of his pecuniary interests in the LLC.
Exozymes Inc. director James Joseph Lalonde received a grant of 10,000 stock options to buy common stock on October 1, 2026, with an exercise price of $6.28 per share. The options vest in 12 quarterly installments: 11 installments of 833 shares and a final installment of 837 shares, beginning December 31, 2026, and ending September 30, 2029, subject to the reporting person's continued service with the issuer.
ExoZymes Inc. (EXOZ) granted director and 10% owner Anthony Digiandomenico a stock option covering 10,000 common shares on October 1, 2026. The option has a $6.28 exercise price and vests in 12 quarterly installments—11 installments of 833 shares and a final installment of 837 shares—beginning December 31, 2026 and ending September 30, 2029, subject to his continued service. It expires October 1, 2033.
Separately, MDB Capital Holdings, LLC held 3,808,476 common shares as of October 1, 2026. Digiandomenico has voting and dispositive authority over those shares and disclaims any interest in them except to the extent of his pecuniary interests in the LLC.
EXOZYMES INC. director James Ulrich Bowie received an option award covering 10,000 shares of common stock on October 1, 2026. The option has an exercise price of $6.28 per share and expires October 1, 2033. It vests in 12 quarterly installments, beginning December 31, 2026, and ending September 30, 2029, subject to continued service with the issuer. Bowie reported direct ownership of 577,910 common shares on October 1, 2026.
EXOZYMES INC. (EXOZ) director Lon E. Bell received 10,000 stock options covering 10,000 shares of common stock, with an exercise price of $6.28 per share. Vesting is subject to his continued service, and the options expire October 1, 2033.
EXOZYMES INC. (EXOZ) reported that Vice President–Finance Nawaz Fouad received a grant of stock options for 45,000 shares of common stock on September 14, 2026, at an exercise price of $6.28 per share. These options vest over three years in twelve equal quarterly installments of 3,750 shares, beginning with the first full calendar quarter after the grant, with the first installment vesting on December 31, 2026 and the final installment on September 30, 2029. The options expire on September 14, 2033. Following this award, Fouad also holds 9,488 shares of common stock directly, and no transactions are reported under any Rule 10b5-1 trading plan.
EXOZYMES INC. (EXOZ) reported that Chief Executive Officer Michael Heltzen increased his direct holdings of common stock through several transactions in August 2026. On August 25–26, 2026, he purchased a total of 855 shares in open market or private transactions at prices between $7.35 and $7.60 per share. On August 19, 2026, he also acquired 8,841 shares as a grant or award at $6.40 per share. No Rule 10b5-1 trading plan is reported for these transactions.
EXOZYMES INC. (EXOZ) reported that Chief Commercial Officer Damien Alan Perriman exercised restricted stock units into common shares. On August 19, 2026, he converted 19,612 RSUs into 19,612 shares of common stock from a January 14, 2026 grant of 62,759 RSUs. Following these transactions, he directly holds 28,499 common shares and 43,147 RSUs that continue to vest periodically.
EXOZYMES INC. (EXOZ) reported that Chief Scientific Officer Korman Tyler Paz exercised 32,964 Restricted Stock Units into 32,964 shares of Common Stock on August 19, 2026. The RSUs convert on a one-for-one basis. Following these transactions, Paz directly holds 762,837 shares of Common Stock and 46,140 RSUs (derivative securities).
EXOZYMES INC. Chief Scientific Officer Korman Tyler Paz reported small open-market sales of company common stock. On April 8, Paz sold 750 shares at an average price of $10.0406 per share, followed by another 750 shares on April 9 at $10.525 per share.
Across the two days Paz sold a total of 1,500 shares and now directly holds 729,123 shares of EXOZYMES INC. common stock. The transactions are classified as open-market sales of non-derivative common stock.
EXOZYMES INC. Chief Commercial Officer Damien Alan Perriman received equity-based compensation on April 1, 2026. He was granted stock options for 146,437 shares of common stock at an exercise price of $9.49 per share and a restricted stock award of 62,759 shares.
The restricted shares vest quarterly at 3,923 shares, with 15,689 shares vesting immediately and a final 3,917-share installment scheduled on April 1, 2029. The options vest monthly at 3,050 shares, with 36,609 shares vesting immediately and a final 3,078-share installment also on April 1, 2029.
After these awards, Perriman directly holds 62,759 common shares from the restricted stock grant and 146,437 stock options, all granted as compensation rather than through open-market buying or selling.
Perriman Damien Alan reported acquisition or exercise transactions in this Form 4 filing.
EXOZYMES INC. Chief Commercial Officer Damien Alan Perriman received a grant of 8,887 shares of common stock on 2026-04-01. The shares were awarded as a compensation-related grant at a reported price of $8.44 per share, rather than through an open-market purchase or sale.
Opgenorth Paul Hideo reported acquisition or exercise transactions in this Form 4 filing.
EXOZYMES INC. reported that Vice President of Development Paul Hideo Opgenorth received a grant of 3,999 shares of common stock on April 1, 2026 at a price of $8.44 per share. Following this compensation-related award, his direct holdings increased to 645,149 shares of EXOZYMES common stock.
Exozymes Inc. Vice President-Finance Nawaz Fouad received a stock award of 5,999 shares of common stock. The shares were granted at a value of $8.44 per share and are reported as a grant, award, or other acquisition rather than an open-market purchase. Following this award, his directly held common stock position increased to 9,488 shares.
Korman Tyler Paz reported acquisition or exercise transactions in this Form 4 filing.
Exozymes Inc. reported that Chief Scientific Officer Tyler Paz Korman received a stock grant of 5,332 shares of common stock on April 1, 2026, at a value of $8.44 per share. Following this compensation-related award, Korman directly holds a total of 730,623 common shares.